Third-Party Tested ≥98% HPLC Purity — USA Shipped

Metabolic & Incretin Research Guide

Cagrilintide: Mechanism, Handling & Research Guide

Also known as: AM833, long-acting amylin analog

Key Facts

Cagrilintide is a metabolic & incretin research peptide (C194H312N54O59S2, MW 4409.01 g/mol). Long-acting synthetic amylin analogue for obesity and metabolic research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification Long-acting amylin receptor agonist
Molecular Formula C194H312N54O59S2
Molecular Weight 4409.01 g/mol
CAS Number 1415456-99-3
Research Half-Life ~7–9 days
Form Lyophilized powder
Research Category Metabolic & Incretin

What is Cagrilintide?

Cagrilintide is a long-acting acylated amylin analogue engineered for extended receptor engagement at the amylin receptor complex (AMY1 and AMY3). Its mechanism involves activating calcitonin and amylin receptors in the area postrema and hypothalamus, modulating satiety signaling and gastric emptying. Compared to pramlintide, the only previously available amylin analogue, cagrilintide offers a substantially longer half-life (approximately 7 days vs. Research also indicates potential benefits in alcohol-related liver disease models, where amylin signaling may reduce hepatic lipid accumulation. The lyophilized powder should be stored at -20C prior to reconstitution with sterile water or bacteriostatic water; reconstituted solutions should be refrigerated at 2-8C. This compound is primarily studied by obesity research institutes, pharmaceutical laboratories investigating incretin-amylin synergy, and academic centers focused on appetite neurobiology and hepatic metabolism.

Cagrilintide Research Applications

In published and preclinical research, Cagrilintide has been studied across the following areas:

  • Metabolic and glucose-regulation research
  • Incretin-pathway combination research
  • Hepatic-injury models
  • Cardiovascular condition exploration

Cagrilintide in Research: Study Context

Cagrilintide is a long-acting amylin analog studied alone and in combination with semaglutide (CagriSema) in published clinical research. In the laboratory the lyophilized peptide is reconstituted with bacteriostatic water; working concentration depends on the assay. Cagrilintide is not FDA-approved and is supplied for research use only.

How Cagrilintide Compares

Researchers frequently evaluate Cagrilintide alongside related compounds:

Cagrilintide — Frequently Asked Questions

Is Cagrilintide legal to buy for research?
Cagrilintide is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.
Does Cagrilintide come with a Certificate of Analysis?
Yes. Every batch of Cagrilintide from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.
What is Cagrilintide and how does it work?
Cagrilintide is a long-acting synthetic analogue of amylin, a hormone co-secreted with insulin from pancreatic beta cells. It binds to amylin receptors (AMY1 and AMY3), which in preclinical models has been observed to influence satiety signaling, gastric emptying rate, and post-meal glucagon secretion. Its acylated fatty acid modification extends its half-life, enabling less frequent in research studies.
What research has been done on Cagrilintide?
Novo Nordisk's Phase 2 trials (published 2021-2023) studied cagrilintide both as a monotherapy and in combination with semaglutide (the CagriSema program). Research data showed statistically significant reductions in body weight compared to placebo. Preclinical studies have also investigated its effects on alcohol-related liver disease models and cardiovascular biomarkers in animal subjects.
How does Cagrilintide compare to Pramlintide?
In comparative studies, cagrilintide demonstrated stronger receptor binding affinity at AMY1 and AMY3 receptors than native amylin or pramlintide.
All research guides